PHARMAXUS: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PHARMAXUS
Largest movements
- Receivables within one year +€13,183
up €13,183 (+122.2%), from €10,791 to €23,974
of which Other amounts receivable: +€11,347
- Cash -€703
down €703 (-41.9%), from €1,676 to €974
mainly Receivables within one year (-€13,183) and Other debts (-€3,827)
- Profit (loss) carried forward +€13,337
up €13,337 (+53.8%), from -€24,786 to -€11,449
- Other debts -€3,827
down €3,827 (-41.2%), from €9,289 to €5,462
- Tax, wage and social debts +€2,698
up €2,698 (+31.3%), from €8,612 to €11,310
of which Taxes: +€1,900
- Trade debts +€392
up €392 (+26.6%), from €1,472 to €1,863
- Gross operating margin +€13,660
up €13,660 (+247.0%), from €5,529 to €19,190
- Taxes +€4,554
new in 2025: €4,554
- Financial charges +€362
up €362 (+301.5%), from €120 to €482
- Financial income +€205
up €205 (+24665.1%), from €1 to €206
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €12,586 | €25,186 | +€12,599 | +100.1% |
| Fixed assets | 21/28 | €119 | - | -€119 | |
| Tangible fixed assets | 22/27 | €119 | - | -€119 | |
| Furniture and vehicles | 24 | €119 | - | -€119 | |
| Current assets | 29/58 | €12,467 | €25,186 | +€12,718 | +102.0% |
| Amounts receivable within one year | 40/41 | €10,791 | €23,974 | +€13,183 | +122.2% |
| Trade receivables | 40 | €10,715 | €12,550 | +€1,836 | +17.1% |
| Other amounts receivable | 41 | €77 | €11,424 | +€11,347 | +14823.0% |
| Cash at bank and in hand | 54/58 | €1,676 | €974 | -€703 | -41.9% |
| Deferred charges and accrued income | 490/1 | - | €238 | +€238 | |
| Total equity and liabilities | 10/49 | €12,586 | €25,186 | +€12,599 | +100.1% |
| Equity | 10/15 | -€6,786 | €6,551 | +€13,337 | |
| Contributions | 10/11 | €18,000 | €18,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€24,786 | -€11,449 | +€13,337 | +53.8% |
| Amounts payable | 17/49 | €19,372 | €18,635 | -€737 | -3.8% |
| Amounts payable within one year | 42/48 | €19,372 | €18,635 | -€737 | -3.8% |
| Trade debts | 44 | €1,472 | €1,863 | +€392 | +26.6% |
| Suppliers | 440/4 | €1,472 | €1,863 | +€392 | +26.6% |
| Taxes, remuneration and social security | 45 | €8,612 | €11,310 | +€2,698 | +31.3% |
| Taxes | 450/3 | €5,237 | €7,137 | +€1,900 | +36.3% |
| Remuneration and social security | 454/9 | €3,375 | €4,174 | +€798 | +23.7% |
| Other amounts payable | 47/48 | €9,289 | €5,462 | -€3,827 | -41.2% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €218 | €119 | -€99 | -45.5% |
| Other operating charges | 640/8 | €946 | €904 | -€41 | -4.4% |
| Gross operating margin | 9900 | €5,529 | €19,190 | +€13,660 | +247.0% |
| Operating profit (loss) | 9901 | €4,366 | €18,167 | +€13,801 | +316.1% |
| Financial income | 75/76B | €1 | €206 | +€205 | +24665.1% |
| Recurring financial income | 75 | €1 | €206 | +€205 | +24665.1% |
| Financial charges | 65/66B | €120 | €482 | +€362 | +301.5% |
| Recurring financial charges | 65 | €120 | €482 | +€362 | +301.5% |
| Profit (loss) for the period before taxes | 9903 | €4,246 | €17,891 | +€13,644 | +321.3% |
| Income taxes | 67/77 | - | €4,554 | +€4,554 | |
| Profit (loss) for the period | 9904 | €4,246 | €13,337 | +€9,090 | +214.1% |
| Profit (loss) for the period to be appropriated | 9905 | €4,246 | €13,337 | +€9,090 | +214.1% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 8 October 2026 via checked.be.